Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator, manufacturer, and
exporter, announces that its Quality Assessment Products
(“
QAPs™”) are now supporting test accuracy within
a program to provide Point-of-Care Testing
(“
PoCT”) for Sexually-Transmitted Infections
(“
STIs”) in remote communities across Australia.
An initial supply of QAPs has been delivered to the end-customer
via Microbix’s regional distributor, r-Biopharm Australia Pty Ltd,
for support of the program.
The program being supported by QAPs is directed
to improving the health of Australians in more-remote areas by
using PoCTs to improve access to diagnosis and treatment of STIs.
The program involves 60 sites across five regions of Australia and
is using a well-known molecular diagnostics
(“MDx”) PoCT instrument system to test for and
distinguish between three bacterial STIs, namely Chlamydia
trachomatis, Neisseria gonorrhea, and Trichomonas vaginalis.
Microbix is supplying its QAPs formatted onto
the FLOQSwabs® of its strategic partner, Copan®, under the
PROCEEDx™FLOQ® brand. The PROCEEDxFLOQ QAPs have been formatted as
multiplex positives that contain whole-genome MDx targets for each
of the three targeted STI pathogens and as STI-free negatives, each
with sample-adequacy control. Microbix’s QAPs dry FLOQSwab®
formulations are validated to be stable for two years at
temperatures as high as 30 Celsius – a critical property for use in
the targeted regions of Australia. Microbix concludes that ease of
access to fast and accurate diagnosis, followed by effective
treatment, is key to reducing the disease burden and healthcare
costs of STIs. It is therefore honoured to be supporting this
Australian program for STI testing in remote communities, which
Microbix believes is providing a worldwide model for helping
underserved populations.
Philip Hill, General Manager of r-Biopharm
Australia commented, “r-Biopharm is pleased that the program will
be delivering world-class diagnostic testing to some of the most
remote populations in Australia. It has been a privilege to work
with the program’s operational team and Microbix to integrate the
use of the best possible test and test-workflow controls into the
program.”
Phil Casselli, SVP of Sales & Business
Development of Microbix stated “We believe that accessible and
accurate testing for STIs is critical to being able to direct
effective treatment and reduce re-transmission. It is often
impractical for more-remote areas to use testing that relies on
distant central labs and they can therefore benefit from the usage
of PoCTs. This program, supported by PROCEEDxFLOQ QAPs, should help
to provide the kind of testing needed in these Australian
communities.”
Microbix’s FLOQSwab-based QAPs support both STIs
and other disease categories, with the full catalogue available at
https://microbix.com and purchase enquiries directed to
customer.service@microbix.com.
About Microbix
BiosystemsMicrobix creates proprietary biological products
for human health, with over 100 skilled employees and annualized
sales targeting C$ 2.0 million per month. It makes a wide range of
critical ingredients and devices for the global diagnostics
industry, notably antigens for immunoassays and its laboratory
quality assessment products (QAPs™) that support clinical lab
proficiency testing, enable assay development and validation, or
help ensure the quality of clinical diagnostic workflows. Its
antigens drive the antibody tests of approximately 100 diagnostics
makers, while QAPs are sold to clinical laboratory accreditation
organizations, diagnostics companies, and clinical laboratories.
Microbix QAPs are now available in over 30 countries, distributed
by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc.,
Diagnostic International Distribution SpA., Labquality Oy, The
Medical Supply Company of Ireland, Neo-Science Equipment LLC,
R-Biopharm AG, SDT Molecular Pte Ltd, Seegene Canada Inc., and
Thomas Scientific LLC. Microbix is ISO 9001 and 13485 accredited,
U.S. FDA registered, Australian TGA registered, Health Canada
establishment licensed, and provides CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably viral transport medium (DxTM™) to
stabilize patient samples for lab-based molecular diagnostic
testing and Kinlytic® urokinase, a biologic thrombolytic drug used
to treat blood clots. Microbix is traded on the TSX and OTCQX, and
headquartered in Mississauga, Ontario, Canada.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, discussion of r-Biopharm
Australia, the products of Microbix or its collaborators,
Microbix’s business and business results, goals or outlook, risks
associated with financial results and stability, development
projects such as those referenced herein or in its corporate
presentation, regulatory compliance and approvals, sales to foreign
jurisdictions, engineering and construction, production (including
control over costs, quality, quantity and timeliness of delivery),
foreign currency and exchange rates, maintaining adequate working
capital or raising further capital on acceptable terms or at all,
and other similar statements concerning anticipated future events,
conditions or results that are not historical facts. These
statements reflect management’s current estimates, beliefs,
intentions and expectations; they are not guarantees of future
performance. The Company cautions that all forward-looking
information is inherently uncertain and that actual performance may
be affected by a number of material factors, many of which are
beyond the Company’s control. Accordingly, actual future events,
conditions and results may differ materially from the estimates,
beliefs, intentions and expectations expressed or implied in the
forward-looking information. All statements are made as of the date
of this news release and represent the Company’s judgement as of
the date of this new release, and the Company is under no
obligation to update or alter any forward-looking information.
Please visit https://microbix.com or
www.sedar.com for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome, CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
Copyright © 2023 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, PROCEEDx™, and QAPs™ are trademarks of
Microbix Biosystems Inc.PROCEEDx®FLOQ® is a trademark of Microbix
Biosystems Inc. in collaboration with Copan Italia S.p.A.Copan®,
FLOQ® and FLOQSwab® are trademarks of Copan Italia S.p.A.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jul 2023 to Jul 2024